You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 8,506,929


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,506,929 protect, and when does it expire?

Patent 8,506,929 protects AMYVID and is included in one NDA.

This patent has fifty-one patent family members in thirty-three countries.

Summary for Patent: 8,506,929
Title:Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Inventor(s): Kung; Hank F. (Wynnewood, PA), Kung; Mei-Ping (Wynnewood, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:12/186,072
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,506,929

Introduction

Patent US 8,506,929, like any other patent, is a complex document that outlines the invention, its scope, and the claims made by the inventors. To analyze this patent, we need to delve into several key aspects, including the determination of inventorship, the scope of the patent claims, and the broader patent landscape.

Determining Inventorship

Inventorship is a critical aspect of any patent application. According to US patent law, the true and only inventors must be listed on the patent application. This involves identifying individuals who conceived the idea or subject matter of the patent claims and reduced it to practice[2].

  • Conception and Reduction to Practice: Conception is defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention. Reduction to practice involves making a working example of the claimed invention or filing a patent application[2].
  • Importance of Correct Inventorship: Incorrect or incomplete identification of inventors can lead to the patent being invalid or unenforceable. This highlights the need for thorough invention disclosure to ensure the patent remains enforceable[2].

Patent Claims and Scope

Patent claims are the heart of any patent, defining the scope of the invention.

Independent Claim Length and Count

Research has shown that metrics such as independent claim length and count can be used to measure patent scope. Narrower claims, as indicated by shorter lengths and fewer counts, are often associated with a higher probability of grant and a shorter examination process[3].

  • Examination Process: The patent examination process tends to narrow the scope of patent claims. This is reflected in changes to claim length and count, which are more significant when the examination duration is longer[3].

Prong Two of Step 2A for Subject Matter Eligibility

For patents facing section 101 rejections, particularly those involving AI inventions, the two-pronged framework introduced by the USPTO is crucial.

  • Prong One: This step determines whether the claim elements recite abstract ideas, such as mathematical concepts or mental processes. If they do, the claim is evaluated further under Prong Two[4].
  • Prong Two: Here, the focus is on whether the claim elements integrate the abstract idea into a practical application. This involves demonstrating an improvement in the functioning of a computer or another technological field[4].

Analyzing Patent US 8,506,929

Patent Details

To analyze the specific patent US 8,506,929, one would need to review the patent document itself. Here are some key points to consider:

  • Title and Abstract: The title and abstract provide a brief overview of the invention.
  • Background of the Invention: This section explains the context and prior art related to the invention.
  • Summary of the Invention: A concise summary of the invention, including its key features.
  • Detailed Description of the Invention: This section provides a detailed explanation of the invention, including drawings and examples.

Claims

The claims section is where the inventors define the scope of their invention.

  • Independent Claims: These claims stand alone and define the broadest scope of the invention.
  • Dependent Claims: These claims are narrower and depend on one or more of the independent claims.

Scope of the Invention

The scope of the invention is determined by the claims. Here, it is essential to identify what is novel and non-obvious about the invention.

  • Novelty and Non-Obviousness: The invention must be new and not obvious to someone with ordinary skill in the relevant field.
  • Enablement and Written Description: The patent must provide enough detail to enable someone with ordinary skill to make and use the invention, and it must describe the invention in sufficient detail[4].

Patent Landscape

Global Dossier and Public Search Facilities

Tools like the Global Dossier and the USPTO Public Search Facility can help in understanding the broader patent landscape.

  • Global Dossier: This service provides access to file histories of related applications from participating IP Offices, helping users to see the patent family and related applications[1].
  • Public Search Facility: Located in Alexandria, VA, this facility offers public access to patent and trademark information in various formats, assisted by trained staff[1].

Industry Trends and Challenges

Understanding the current trends and challenges in the patent landscape is crucial.

  • Patent Quality Debates: There are ongoing debates about the quality of patents, with concerns over overly broad patents and their impact on innovation[3].
  • AI Inventions: The rise of AI inventions has introduced new challenges in determining subject matter eligibility under section 101 of the US patent law[4].

Practical Tips for Patent Applicants

Crafting Effective Arguments

For patents facing section 101 rejections, especially AI inventions, it is vital to craft strong arguments under Prong Two.

  • Demonstrating Practical Application: Show that the claims are directed to a specific, concrete technological advancement or solution to a technical problem[4].
  • Building a Compelling Narrative: Formulate a narrative that highlights the unique aspects of the invention and its practical utility and real-world impact[4].

Avoiding Common Pitfalls

  • Inventorship Errors: Ensure that the true and only inventors are listed to avoid invalidation of the patent[2].
  • Overly Broad Claims: Narrow claims are generally more favorable during the examination process[3].

Key Takeaways

  • Correct Inventorship: Accurate identification of inventors is crucial for the validity and enforceability of the patent.
  • Patent Scope Metrics: Independent claim length and count can be used to measure patent scope and predict examination outcomes.
  • Subject Matter Eligibility: For AI inventions, demonstrating practical application under Prong Two of Step 2A is essential.
  • Thorough Disclosure: Detailed invention disclosure ensures that the patent remains enforceable.
  • Global Dossier and Public Search Facilities: These tools are invaluable for understanding the broader patent landscape.

FAQs

What is the importance of correct inventorship in a patent application?

Correct inventorship is crucial because listing more or fewer than the true inventors can lead to the patent being invalid or unenforceable.

How do independent claim length and count affect the patent examination process?

Narrower claims, as indicated by shorter lengths and fewer counts, are associated with a higher probability of grant and a shorter examination process.

What is Prong Two of Step 2A in the context of patent subject matter eligibility?

Prong Two involves demonstrating that the claim elements integrate the abstract idea into a practical application, showing an improvement in the functioning of a computer or another technological field.

How can one ensure the validity and enforceability of a patent?

Ensuring correct inventorship, providing thorough invention disclosure, and avoiding overly broad claims are key steps to ensure the validity and enforceability of a patent.

What tools are available for understanding the broader patent landscape?

Tools like the Global Dossier and the USPTO Public Search Facility provide valuable insights into the patent landscape by offering access to related applications and patent information.

Sources

  1. USPTO Public Search Facility - https://www.uspto.gov/patents/search
  2. Determining Inventorship for US Patent Applications - https://agsci.oregonstate.edu/sites/agsci/files/main/research/vrc_release_inventorship-gattari.pdf
  3. Patent Claims and Patent Scope - https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  4. The Importance of Prong Two of Step 2A for AI Inventions - https://www.bakerbotts.com/thought-leadership/publications/2024/september/the-importance-of-prong-two-of-step-2a-for-ai-inventions
  5. 2019 Revised Patent Subject Matter Eligibility Guidance - Cited in [4] and

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,506,929

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN Yes No 8,506,929 ⤷  Subscribe Y Y AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT ⤷  Subscribe
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-002 Apr 6, 2012 DISCN Yes No 8,506,929 ⤷  Subscribe Y Y AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT ⤷  Subscribe
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes 8,506,929 ⤷  Subscribe Y Y AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,506,929

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1999109 ⤷  Subscribe C300600 Netherlands ⤷  Subscribe
European Patent Office 1999109 ⤷  Subscribe CA 2013 00035 Denmark ⤷  Subscribe
European Patent Office 1999109 ⤷  Subscribe PA2013016 Lithuania ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.